Source comparison
PT-141 Kisspeptin for Hormonal + Central Pathways: Research Application Comparison
Primary Target Melanocortin MC4R in paraventricular nucleus KISS1R (GPR54) on GnRH neurons in arcuate nucleus Dual pathway: CNS arousal + HPG axis activation PT-141 alone for arousal dysfunction; kisspeptin alone for hypogonadotropic states; combination for pr
This comparison does not assign a generated winner or score.
- Primary Target
- Melanocortin MC4R in paraventricular nucleus
- KISS1R (GPR54) on GnRH neurons in arcuate nucleus
- Dual pathway: CNS arousal + HPG axis activation
- PT-141 alone for arousal dysfunction; kisspeptin alone for hypogonadotropic states; combination for protocols requiring both CNS and hormonal restoration
- Mechanism
- Increases hypothalamic dopamine and oxytocin release
- Stimulates pulsatile GnRH → LH/FSH secretion → gonadal steroid production
- PT-141 modulates neurotransmitter tone; kisspeptin restores reproductive hormone pulsatility
- Mechanisms do not overlap. Receptor systems are entirely distinct
- Onset
- 45–90 minutes subcutaneously
- LH elevation detectable within 30–60 minutes IV; testosterone rise takes 6–12 hours
- PT-141 effects immediate; kisspeptin hormonal effects delayed
- PT-141 is on-demand; kisspeptin requires multi-day or pulsed administration for sustained LH elevation
- Half-Life
- ~2.7 hours (effects dissipate within 6–8 hours)
- ~30 minutes for kisspeptin-10 (requires continuous or pulsatile infusion)
- PT-141 single-dose; kisspeptin pulsed dosing every 90–120 minutes or continuous low-dose infusion
- Kisspeptin's short half-life mimics endogenous GnRH pulsatility but complicates practical dosing outside clinical settings
- Hormonal Impact
- None. Does not alter LH, FSH, testosterone, or estradiol
- Significant. Increases LH pulse frequency by 80–150% at therapeutic doses
- PT-141 zero; kisspeptin substantial
- PT-141 will not restart endogenous testosterone production; kisspeptin will not improve libido if HPG axis is already functional
- Research Context
- Hypoactive sexual desire studies, arousal pathway mapping, melanocortin system investigation
- Hypogonadotropic hypogonadism models, GnRH deficiency, reproductive endocrine axis studies
- Protocols requiring both CNS arousal restoration and gonadotropin recovery (e.g., post-exogenous androgen washout)
- Combining both addresses separate physiological deficits. Not synergistic but complementary